Q3 2021 BioArctic AB Earnings Call Transcript
Hello, and welcome to the BioArctic webcast with teleconference. (Operator Instructions) Just to remind you, this conference call is being recorded. Today, I'm pleased to present CEO, Gunilla Osswald; and CFO, Jan Mattsson. Please go ahead with your meeting.
()-
Thank you, and good morning, and welcome to BioArctic's Third Quarter Report 2020. I I'm Gunilla Osswald and I'm the CEO of BioArctic. I will share this presentation with our CFO, Jan Mattsson. I think it has been a great quarter for BioArctic and lecanemab. Our partner, Eisai, has after discussions with the U.S. FDA initiated a rolling submission for an accelerated approval for lecanemab in the U.S.
If it gets approved, lecanemab could thereby potentially be helping patients even earlier than previously expected, and I will talk more about that in the presentation here today. Next slide, please. BioArctic is listed on nasdaq.com midcap, and this is our disclaimer. Next slide, please.
BioArctic is a unique Swedish
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |